(Q33826201)

29 July 2017

1 reference

title

Platelet glycoprotein IIb/IIIa receptor antagonists: current concepts and future directions (English)

1 reference

29 July 2017

Ferguson JJ

1

1 reference

PubMed ID

10651385

29 July 2017

Zaqqa M

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

58

1 reference

29 July 2017

6

1 reference

29 July 2017

965-982

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00002

29 July 2017

0 references

cites work

Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety

1 reference

12 December 2020

Safe use of platelet GP IIb/IIIa inhibitors.

1 reference

12 December 2020

Fibrinogen and fibrin

1 reference

12 December 2020

Role of thrombosis in atherosclerosis and its complications

1 reference

12 December 2020

Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic Strategy

1 reference

12 December 2020

The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets

1 reference

12 December 2020

Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II

1 reference

12 December 2020

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

1 reference

12 December 2020

Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Compl

1 reference

12 December 2020

Amino acid sequences in fibrinogen mediating its interaction with its platelet receptor, GPIIbIIIa

1 reference

12 December 2020

Fibrinogen competes with von Willebrand factor for binding to the glycoprotein IIb/IIIa complex when platelets are stimulated with thrombin

1 reference

12 December 2020

The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury

1 reference

12 December 2020

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

12 December 2020

Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis

1 reference

12 December 2020

von Willebrand factor

1 reference

12 December 2020

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

12 December 2020

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

12 December 2020

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

12 December 2020

Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the γ chain of human fibrinogen and is not involved in the fibrin polymerization reaction

1 reference

12 December 2020

Rapid platelet-function assay: an automated and quantitative cartridge-based method

1 reference

12 December 2020

Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

1 reference

12 December 2020

Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell-binding domain of fibronectin

1 reference

12 December 2020

Pathology of arterial thrombosis

1 reference

12 December 2020

Description of an in vitro platelet function analyzer--PFA-100

1 reference

12 December 2020

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

12 December 2020

Signaling through G proteins in platelets: to the integrins and beyond

1 reference

12 December 2020

Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex

1 reference

12 December 2020

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

12 December 2020

Preliminary data from a field trial of the PFA-100 system

1 reference

12 December 2020

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy

1 reference

12 December 2020

Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study

1 reference

12 December 2020

Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the .gamma. chain

1 reference

12 December 2020

Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb-IIIa

1 reference

12 December 2020

The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

1 reference

12 December 2020

Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model

1 reference

12 December 2020

The platelet membrane glycoprotein IIb-IIIa complex.

1 reference

12 December 2020

Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs

1 reference

12 December 2020

Cyclic RGD peptide analogues as antiplatelet antithrombotics

1 reference

12 December 2020

1 reference

12 December 2020

Platelet glycoprotein IIb-IIIa is associated with 21-kDa GTP-binding protein

1 reference

12 December 2020

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

12 December 2020

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

12 December 2020

Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study

1 reference

12 December 2020

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

12 December 2020

Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study

1 reference

12 December 2020

Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tiro

1 reference

12 December 2020

Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy

1 reference

12 December 2020

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

12 December 2020

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

12 December 2020

Integrins: versatility, modulation, and signaling in cell adhesion

1 reference

12 December 2020

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study

1 reference

12 December 2020

Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators

1 reference

12 December 2020

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

12 December 2020

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

12 December 2020

Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators

1 reference

12 December 2020

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

12 December 2020

Combined thrombolytic and platelet glycoprotein IIb/IIIa inhibitor therapy for acute myocardial infarction: will pharmacological therapy ever equal primary angioplasty?

1 reference

12 December 2020

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

1 reference

12 December 2020

10.2165/00003495-199958060-00002

Identifiers

DOI

1 reference

PubMed ID

10651385

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10651385